Pipeline Chasing Dupixent, a biotech aims to make better antibody drugs for eczema pharminent August 11, 2026
M&A / Deals Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments pharminent August 7, 2026
M&A / Deals Argenx deepens immuno expertise with $2.2B Forte Biosciences buy pharminent July 27, 2026
Clinical Data Evommune ends development of lead asset in chronic hives after mid-stage efficacy woes pharminent June 30, 2026
Clinical Data Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test pharminent June 11, 2026
Clinical Data Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity pharminent June 4, 2026
Clinical Data AbiVax falls as safety worries cloud ‘landmark’ immune drug results pharminent June 2, 2026
M&A / Deals Apogee investors riled by $1.3B royalty deal, as eczema drug matches Lilly’s Ebglyss pharminent May 27, 2026
Pipeline Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update pharminent May 20, 2026
Clinical Data AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritis pharminent May 20, 2026
Clinical Data UCB reports positive outcomes for bimekizumab in psoriatic arthritis pharminent May 19, 2026
M&A / Deals Degron adds $40M to series A, supporting immunology plans for molecular glue platform pharminent May 14, 2026
M&A / Deals UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases pharminent May 4, 2026
M&A / Deals Coultreon banks $125M to support testing of former Galapagos immune drug pharminent April 28, 2026
Clinical Data Oruka surges as long-acting psoriasis drug shows early promise pharminent April 27, 2026
Commercial Sanofi defends Dupixent patents, but execs insist it has nothing to do with CEO change pharminent April 23, 2026
M&A / Deals BioAegis and Prenosis partner for inflammatory disease therapies pharminent April 22, 2026
M&A / Deals BioAegis and Prenosis partner for inflammatory disease therapies pharminent April 22, 2026
Clinical Data BioAge says early data suggest ‘best-in-class’ potential for inflammation drug pharminent April 21, 2026
M&A / Deals Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers pharminent April 15, 2026
M&A / Deals BMS makes a Beeline, bringing 5 assets to biotech’s $300M precision immunology debut pharminent April 15, 2026
Clinical Data Spyre drug for inflammatory bowel disease shows promise in early study pharminent April 13, 2026
Policy / Pricing AbbVie Puts Humira on TrumpRx at Steep Discount as Tariff Threat Solidifies pharminent April 7, 2026
